Loading...
XSTOEXPRS2
Market cap4mUSD
Dec 23, Last price  
22.00SEK
1D
5.77%
1Q
2,225.58%
Jan 2017
205.45%
IPO
224.95%
Name

ExpreS2ion Biotech Holding AB

Chart & Performance

D1W1MN
XSTO:EXPRS2 chart
P/E
—
P/S
6.55
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.67%
Rev. gr., 5y
-4.48%
Revenues
7m
+38.62%
6,664,9616,615,05604,652,0009,795,0008,868,00013,829,0005,259,00012,234,0005,086,0007,050,000
Net income
-91m
L-22.94%
688,660279,308-8,438,149-8,538,000-9,835,000-16,822,000-16,703,000-31,713,000-43,925,000-118,605,000-91,401,000
CFO
-101m
L+1.28%
-7,021,000-8,608,000-12,879,000-12,691,000-18,175,000-45,646,000-99,614,000-100,887,000
Earnings
May 30, 2025

Profile

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.
URL
https://www.expres2ionbio.com
IPO date
Jul 29, 2016
Employees
32
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,050
38.62%
5,086
-58.43%
12,234
132.63%
Cost of revenue
55,066
76,405
20,844
Unusual Expense (Income)
NOPBT
(48,016)
(71,319)
(8,610)
NOPBT Margin
Operating Taxes
(8,566)
(7,976)
(3,591)
Tax Rate
NOPAT
(39,450)
(63,343)
(5,019)
Net income
(91,401)
-22.94%
(118,605)
170.02%
(43,925)
38.51%
Dividends
Dividend yield
Proceeds from repurchase of equity
60,719
75,960
83,304
BB yield
-62.36%
-12.18%
-7.03%
Debt
Debt current
275
1,763
1,918
Long-term debt
2,872
176
382
Deferred revenue
(191)
Other long-term liabilities
1,914
3,478
Net debt
(54,475)
(110,592)
(34,834)
Cash flow
Cash from operating activities
(100,887)
(99,614)
(45,646)
CAPEX
(2,015)
(383)
(715)
Cash from investing activities
(2,015)
105,325
(100,921)
Cash from financing activities
47,836
61,460
74,545
FCF
(40,309)
(61,003)
(6,975)
Balance
Cash
57,597
110,974
138,880
Long term investments
25
1,557
(101,746)
Excess cash
57,270
112,277
36,522
Stockholders' equity
(934,488)
(235,324)
(125,897)
Invested Capital
1,001,563
342,416
271,639
ROIC
ROCE
EV
Common stock shares outstanding
46,149
37,739
32,248
Price
2.11
-87.24%
16.53
-55.03%
36.76
237.25%
Market cap
97,373
-84.39%
623,821
-47.38%
1,185,453
468.62%
EV
42,898
752,732
1,279,976
EBITDA
(46,417)
(70,103)
(6,801)
EV/EBITDA
Interest
501
871
Interest/NOPBT